ESSENCE is Novo Nordisk's registrational Phase 3 trial of once-weekly semaglutide 2.4 mg in non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced fibrosis. The trial enrolled adults with biopsy-confirmed MASH and tested whether GLP-1 receptor agonism, the same mechanism that drives weight loss in Wegovy, can deliver histologic improvement in the liver.
The primary readout showed steatohepatitis resolution without fibrosis worsening in 63% of semaglutide-treated patients versus 34% on placebo, plus a higher rate of one-stage fibrosis improvement without MASH worsening. Those results supported the FDA's 2025 accelerated approval of semaglutide for MASH, making it the second drug class cleared for the disease after Madrigal's resmetirom. At EASL 2026, Novo extended the ESSENCE narrative with Japanese subgroup analyses, menopausal-women data, and real-world MASH burden numbers tying steatohepatitis to quality-of-life and healthcare-cost outcomes.
Stories here cover ESSENCE readouts, label expansion work, and the broader incretin-MASH comparison with survodutide, pemvidutide, and others. See #semaglutide, #mash, and #novo-nordisk for adjacent threads.
Novo Nordisk extended its EASL 2026 ESSENCE presentation cycle into Day 2 with real-world evidence quantifying the MASH disease burden — documenting significant quality-of-life impairment and escalating healthcare costs in MASH patients — alongside the Japanese MASH and menopausal women subgroup analyses presented Day 1. The data builds the health-economic case for semaglutide 2.4 mg following the August 2025 FDA MASH-with-fibrosis approval. MASH affects roughly 1 in 3 people living with overweight or obesity worldwide, with the majority undiagnosed. Novo's 'Love Your Liver' EASL initiative offered on-site MASH testing for attendees. The real-world burden data complements the ESSENCE Phase 3 efficacy story by establishing the economic and quality-of-life rationale for early MASH intervention — a payer-facing argument as the GLP-1 MASH indication scales into 2026-2027 against the THR-β, FGF21, and GLP-1/glucagon competitor classes.
Novo Nordisk presented two ESSENCE Phase 3 subgroup analyses at EASL 2026 today. The Japanese MASH subgroup analysis extends the semaglutide 2.4 mg efficacy and safety case to Asian populations where MASLD and MASH develop at lower body-mass-index thresholds and involve distinct metabolic risk profiles. The Menopause subgroup analysis covers women in menopause, where hormonal changes accelerate liver disease progression and metabolic deterioration. Both analyses show consistent hepatic safety profile and efficacy across the underrepresented groups. The August 2025 FDA MASH-with-fibrosis approval of semaglutide 2.4 mg was based on the broader ESSENCE Phase 3 cohort; the EASL Day 1 presentations strengthen the global labeling case across non-Western populations and the menopausal-women subgroup that has historically been underrepresented in MASH clinical trials. Real-world evidence data presented today documents quality-of-life impairment and healthcare-cost escalation in MASH patients.
EASL 2026 Day 1 in Barcelona delivered the most concentrated MASH-therapeutics data cycle of 2026. The peptide-mechanism cohort: Altimmune pemvidutide qFibrosis fibrosis regression (LBP-036), MetaVia DA-1726 48 mg Phase 1 noninvasive liver assessment, Novo Nordisk ESSENCE Japanese/menopausal subgroups. The non-peptide-mechanism cohort: Arrowhead ARO-INHBE RNAi (Activin E/ALK7 pathway), Galectin Therapeutics belapectin NAVIGATE (galectin-3 inhibitor), Sagimet Biosciences denifanstat + resmetirom combination (FASN inhibitor + Madrigal's Rezdiffra), Madrigal eight-poster Rezdiffra data drop on cardiovascular and portal hypertension markers. The combined cycle reframes MASH as a multi-mechanism battleground rather than a single-class indication — GLP-1/glucagon peptides compete against thyroid-hormone-receptor agonism, RNAi, galectin-3 inhibition, FASN inhibition, and emerging combinations. Thursday May 28 brings the Altimmune pemvidutide oral presentation at 17:00 CEST; Friday May 29 brings ASCO opening in Chicago to anchor the parallel peptide-oncology cycle.
The European Association for the Study of the Liver (EASL) Congress 2026 opens Wednesday May 27 in Barcelona with a heavy peptide-MASH slate. Novo Nordisk's ESSENCE Phase 3 program leads with liver-safety subgroup analyses (Japanese MASH cohort, women in menopause), building on the August 2025 FDA approval of semaglutide for MASH-with-fibrosis. Eli Lilly's retatrutide MASLD Phase 3 (NCT06859268) is enrolling on the 86% Phase 2 liver-fat reduction baseline. Boehringer Ingelheim survodutide SYNCHRONIZE-1 Phase 3 MASH data is expected late 2026 with positive results potentially establishing the GLP-1/glucagon dual agonist as standard of care alternative to semaglutide. MetaVia's vanoglipel (DA-1241, GPR119 agonist) Phase 2a + resmetirom combination work presented at ECO 2025 anchors the combination-MASH therapy thesis. The EASL plenaries plus the May 21 TRIUMPH-1 readout reframe MASH as a peptide-mechanism battleground rather than a single-drug indication.
Eight days ahead of EASL Congress 2026 in Barcelona (May 27-30), Novo Nordisk released new analyses from the Phase 3 ESSENCE program showing semaglutide 2.4 mg holds a favorable hepatic safety profile across MASH subgroups, including the first dedicated Japanese MASH cohort and a women-in-menopause subset. Gastrointestinal events remained the leading adverse-event signal, with small discontinuation rates. MASH affects an estimated 250 million people globally with roughly 9 in 10 cases undiagnosed; the trial data reinforce the FDA's August 2025 MASH-with-fibrosis approval and broaden the prescribing case ahead of the EASL plenaries.